

NHL: Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

Pathology: _____ Stage: _____

Line of Therapy: _____ ICD-10 Code: _____

Biomarkers/Characteristics: (select all that apply)

17p deletion: __Absent __Present

TP53 status: __Mutation absent __Mutation present

First Line of Therapy (1st Line)

- Any / All Stages
 - Any 17p/TP53 status
 - Acalabrutinib (Calquence)
 - Ibrutinib (Imbruvica)
 - Zanabrutinib (Brukinsa)
 - Without 17p Deletion AND Without TP53 Mutation
 - Venetoclax (Venclexta) and obinutuzumab (Gazyva)

Second Line of Therapy (2nd Line)

- Recurrent / Relapsed Disease
 - Any 17p/TP53 status
 - Acalabrutinib (Calquence)
 - Venetoclax (Venclexta) and rituximab
 - Zanabrutinib (Brukinsa)

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered “on pathway.” However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.

